Filing Flows › 8-K events › GeoVax Labs
GeoVax Labs: departure or appointment of directors and officers
Form 8-K filed Nov 9, 2026 · items 5.02
What the filing says
Effective November 5, 2026, the Board of Directors appointed Shahin Behroyan as a director of the Company. Behroyan was appointed directly by the Board of Directors, by the affirmative vote of a majority of the directors then in office.
Read the filing on SEC EDGAR →
What usually followsAcross 39,189 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →
What this kind of filing means
Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.
GeoVax Labs at a glance
GeoVax Labs, Q2 2025: revenue $852K (+184% year over year), operating margin -635.8%. The chart follows the revenue to costs, profit and cash.
GeoVax Labs: every quarter, Q/Q and Y/Y, holders and guidance →
GeoVax Labs’s other material 8-Ks
- Nov 6, 2026 — CEO changes
- Oct 27, 2026 — FDA decisions GeoVax Enters into $1 Million Revolving Loan Agreement
Other recent ceo changes
- Concentra Group Holdings Parent Nov 9, 2026
- Evolv Technologies Holdings Nov 9, 2026
- Goodyear Tire & Rubber Nov 9, 2026
- KBR Nov 9, 2026
- Vistance Networks Nov 9, 2026
- Agnt Nov 9, 2026
- Sirius XM Holdings Nov 9, 2026
- Datavault AI Nov 9, 2026
- Newell Brands Nov 9, 2026
- Sonoco Products Nov 9, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.